Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

(2022) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

(2022) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment

(2021) Moez Ghumman et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety

(2021) Yi-You Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

(2021) Fabrizio Facchinetti et al.   Frontiers in Pharmacology

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases

(2020) Jonathan E. Phillips   Frontiers in Pharmacology

A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung

(2020) Takashi Matsuhira et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Phosphodiesterases as therapeutic targets for respiratory diseases

(2019) Haoxiao Zuo et al.   PHARMACOLOGY & THERAPEUTICS

Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)

(2019) Huihui Ti et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

(2018) Heng Li et al.   Frontiers in Pharmacology

Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy

(2017) Yasunori Nio et al.   FASEB JOURNAL

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

(2017) Jeffrey Crowley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease

(2016) Mario Cazzola et al.   Expert Opinion on Drug Discovery

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

(2016) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)

(2014) Monalisa F. Azevedo et al.   ENDOCRINE REVIEWS

Advances in targeting cyclic nucleotide phosphodiesterases

(2014) Donald H. Maurice et al.   NATURE REVIEWS DRUG DISCOVERY

Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior

(2014) Rolf T. Hansen et al.   PSYCHOPHARMACOLOGY

Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801

(2012) Olga A.H. Reneerkens et al.   BEHAVIOURAL BRAIN RESEARCH

Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes – A role for the transcription factor NFAT and phosphodiesterase 3B

(2012) Bilal Omar et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder

(2012) Masahiro Fujita et al.   BIOLOGICAL PSYCHIATRY

Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility Through Interacting With Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart

(2012) Sanja Beca et al.   CIRCULATION RESEARCH

Cyclic Nucleotide Phosphodiesterase 3 Signaling Complexes

(2012) F. Ahmad et al.   HORMONE AND METABOLIC RESEARCH

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms

(2012) Olga A.H. Reneerkens et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Dual inhibitor of PDE7 and GSK-3 – VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice

(2012) Tatiana V. Lipina et al.   NEUROPHARMACOLOGY

Evaluation of fibrosis in precision-cut tissue slices

(2012) I. M. Westra et al.   XENOBIOTICA

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

(2011) Klaus F. Rabe   BRITISH JOURNAL OF PHARMACOLOGY

Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility

(2011) Najma Begum et al.   CURRENT OPINION IN PHARMACOLOGY

Phosphodiesterases and regulation of female reproductive function

(2011) Marco Conti   CURRENT OPINION IN PHARMACOLOGY

Activation of PDE10 and PDE11 Phosphodiesterases

(2011) Ronald Jäger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Integrating mechanisms of pulmonary fibrosis

(2011) Thomas A. Wynn   JOURNAL OF EXPERIMENTAL MEDICINE

Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling

(2011) Y.-F. Li et al.   JOURNAL OF NEUROSCIENCE

Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients

(2011) Malgorzata Labuda et al.   MEDIATORS OF INFLAMMATION

Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5′-diphospho-glucuronosyltransferase (UGT2B17) gene.

(2011) Lena Ekström et al.   Pharmacogenetics and Genomics

Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions

(2011) Sharron H. Francis et al.   PHYSIOLOGICAL REVIEWS

Neuronal Nitric Oxide Synthase Supports Renin Release During Sodium Restriction Through Inhibition of Phosphodiesterase 3

(2010) Johan Sällström et al.   AMERICAN JOURNAL OF HYPERTENSION

Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis

(2010) Brett Ley et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma

(2010) S.-L. Catherine Jin et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion

(2010) Jens Selige et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

(2009) J Cortijo et al.   BRITISH JOURNAL OF PHARMACOLOGY

cGMP-dependent protein kinase II and aldosterone secretion

(2009) Beate Spießberger et al.   FEBS Journal

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis

(2009) Bibiana Bielekova et al.   Multiple Sclerosis Journal

Phosphodiesterase 8B Gene Variants Are Associated with Serum TSH Levels and Thyroid Function

(2008) Lisette Arnaud-Lopez et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change

(2008) Kirsty F. Mackenzie et al.   BIOCHEMICAL JOURNAL

NO-mediated cGMP synthesis in cultured cholinergic neurons from the basal forebrain of the fetal rat

(2008) J. de Vente et al.   BRAIN RESEARCH

The Efficacy and Safety of Cilomilast in COPD

(2008) Stephen Rennard et al.   DRUGS

PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries

(2008) António José Santos-Silva et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury

(2007) Y. P. de Visser et al.   EUROPEAN RESPIRATORY JOURNAL